Transthyretin Amyloidosis Treatment Market Outlook 2024: Exclusive Report By The Business Research Company

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Transthyretin Amyloidosis Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research..

The transthyretin amyloidosis treatment market size is expected to see strong growth in the next few years. It will grow to $7.42 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to expanded therapeutic pipeline, increased genetic screening, global efforts for rare disease awareness, personalized medicine approaches, improved access to treatment.. Major trends in the forecast period include emergence of combination therapies, strategic partnerships for drug development, focus on targeting peripheral and cardiac manifestations, implementation of patient education programs, incorporation of real-world evidence in treatment guidelines..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp

Market Segmentation:
The transthyretin amyloidosis treatment market covered in this report is segmented -

1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

Major Driver - Increased Research And Development Investments Propel Growth In The Transthyretin Amyloidosis Treatment Market
Rising investments in research and development are expected to propel the growth of the transthyretin amyloidosis treatment market going forward. Research and development (R&D) investments include financial resources allocated to activities aimed at advancing scientific knowledge, developing new technologies, creating innovative products, and improving existing processes. Increased funding in research and development enables the discovery and development of innovative treatment approaches for transthyretin amyloidosis, including novel drugs, gene therapies, and precision medicine techniques, offering patients more effective and targeted treatment options. For instance, in December 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company engaged in the development of Vutrisiran, a treatment of ATTR amyloidosis, increased its research and development investment to $883,015 in 2022 from $792,156 in 2021, reflecting a growth of 11.49%. Therefore, the rising investment in research and development will drive the growth of the transthyretin amyloidosis treatment market.

Competitive Landscape:
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc, Abbvie Inc, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, GSK Plc, Novo Nordisk A/S, Merck & Co. Inc, Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc, Acrotech Biopharma Inc, Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc, Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Top Trend - Innovative Orphan Drug Combinations Transforming The Landscape Of Transthyretin Amyloidosis Treatment
Major companies in the transthyretin amyloidosis treatment market focus on developing innovative and specialized treatments, such as orphan drugs, to enhance patient outcomes and expand treatment options. Eplontersen is an orphan drug specifically designed to treat transthyretin amyloidosis condition, often receiving regulatory benefits to support its development. For instance, in March 2023, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, received The Food and Drug Administration (FDA) approval of a new drug application for Eplontersen, an experimental orphan drug intended for the treatment of familial transthyretin-mediated amyloid, leading to progressive polyneuropathy. Eplontersen is a pharmaceutical agent developed to mitigate the synthesis of transthyretin (TTR) protein to address both the hereditary and non-hereditary variations of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA granted Eplontersen orphan drug designation in 2022.`

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Transthyretin Amyloidosis Treatment Market Characteristics
3. Transthyretin Amyloidosis Treatment Market Trends And Strategies
4. Transthyretin Amyloidosis Treatment Market - Macro Economic Scenario
5. Transthyretin Amyloidosis Treatment Market Size And Growth
…..
27. Transthyretin Amyloidosis Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.